TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17512159

Group type: EXPERIMENTAL
Intervention: Assessment period before treatment entry
Number of subjects: 577

Group type: EXPERIMENTAL
Intervention: Treatment entry period
Number of subjects: 577
Study: 16502748

Group type: EXPERIMENTAL
Intervention: Visual cues (high-contrast transverse lines on the floor)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Auditory cues (rhythmic sounds matching average step time)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Baseline condition
Number of subjects: 14
Study: 14746787

Group type: EXPERIMENTAL
Intervention: Casting calcification cases
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control cases
Number of subjects: 50
Study: 11713727

Group type: EXPERIMENTAL
Intervention: Acellular dermal graft (ADG) on one peritonsillar fossa
Number of subjects: 10

Group type: COMPARATOR
Intervention: No treatment on the control side
Number of subjects: 10
Study: 9142567

Group type: EXPERIMENTAL
Intervention: Yoga training for one month
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (usual routine)
Number of subjects: 30
Study: 8004613

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy for younger or premenopausal women
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen for older or postmenopausal women with estrogen receptor-positive tumors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjuvant therapy (general)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen
Number of subjects: 0
Study: 3555968

Group type: EXPERIMENTAL
Intervention: bufexamac (20 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: methylprednisolone (40 mg)
Number of subjects: 40
Study: 29980233

Group type: EXPERIMENTAL
Intervention: hemodynamic monitoring using hTEE technology
Number of subjects: 500

Group type: COMPARATOR
Intervention: standard hemodynamic monitoring (central venous catheter, pulmonary artery catheter, or conventional echocardiography)
Number of subjects: 500
Study: 27932628

Group type: COMPARATOR
Intervention: non‐testimonial text warning labels
Number of subjects: 924

Group type: EXPERIMENTAL
Intervention: non‐testimonial PWL
Number of subjects: 924

Group type: EXPERIMENTAL
Intervention: image only testimonial PWL
Number of subjects: 924

Group type: EXPERIMENTAL
Intervention: image + personal details testimonial PWL
Number of subjects: 924
Study: 26187674

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent
Number of subjects: 8719

Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stent
Number of subjects: 8719

Group type: COMPARATOR
Intervention: Both stent types
Number of subjects: 8719
Study: 23121081

Group type: EXPERIMENTAL
Intervention: Self-surveillance for alarm
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Home monitoring with CareLink
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (ICDs not under advisory)
Number of subjects: 160
Study: 21110088

Group type: EXPERIMENTAL
Intervention: Low MeHg (0.76 mg kg⁻¹)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medium MeHg (7.88 mg kg⁻¹)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High MeHg (16.22 mg kg⁻¹)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (0.04 mg kg⁻¹)
Number of subjects: 0
Study: 18342222

Group type: EXPERIMENTAL
Intervention: Direct Stenting (DS)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional Stenting (CS)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 17190953

Group type: EXPERIMENTAL
Intervention: Cardiac (123)I‐metaiodobenzylguanidine uptake
Number of subjects: 0
Study: 12660669

Group type: EXPERIMENTAL
Intervention: High-dose furosemide (500-1000 mg) plus hypertonic saline solution (HSS) infusion (150 mL of 1.4%-4.6% NaCl) twice a day for 6 to 12 days.
Number of subjects: 107

Group type: COMPARATOR
Intervention: High-dose furosemide (500-1000 mg) as bolus twice a day for 6 to 12 days without HSS.
Number of subjects: 107
Study: 10735416

Group type: EXPERIMENTAL
Intervention: Modified ultrafiltration (MUF) after hypothermic CPB
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Modified ultrafiltration (MUF) after normothermic CPB
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control group (no MUF) after hypothermic CPB
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control group (no MUF) after normothermic CPB
Number of subjects: 97
Study: 9365428

Group type: EXPERIMENTAL
Intervention: 30 mL syrup of ipecac administered at 5 minutes after ingestion of 3900 mg acetaminophen
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 30 mL syrup of ipecac administered at 30 minutes after ingestion of 3900 mg acetaminophen
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 30 mL syrup of ipecac administered at 60 minutes after ingestion of 3900 mg acetaminophen
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (no ipecac administration)
Number of subjects: 10
Study: 8261835

Group type: COMPARATOR
Intervention: famotidine 20 mg twice a day
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: famotidine 40 mg twice a day
Number of subjects: 474
Study: 3493854

Group type: EXPERIMENTAL
Intervention: Trivalent live, oral polio vaccine (Sabin)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (received initial dose at 2 months of age)
Number of subjects: 200
Study: 29609704

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) treatment
Number of subjects: 70

Group type: COMPARATOR
Intervention: Non-CPAP (best medical treatment)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: CPAP treatment
Number of subjects: 70
Study: 27394134

Group type: COMPARATOR
Intervention: Resistance Exercise Training (RET)
Number of subjects: 200
Study: 25344393

Group type: EXPERIMENTAL
Intervention: TEAMS therapy plus treatment‐as‐usual (TAU)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: TEAMS therapy
Number of subjects: 84

Group type: COMPARATOR
Intervention: TAU
Number of subjects: 84
Study: 23549692

Group type: EXPERIMENTAL
Intervention: Isokinetic testing at 120° · s‐1
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Isokinetic testing at 60° · s‐1
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Isokinetic testing at 90° · s‐1
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Isokinetic testing at 180° · s‐1
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (healthy males)
Number of subjects: 20
Study: 20686425

Group type: EXPERIMENTAL
Intervention: Brief pain intervention (PAIN)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Disease education attention control intervention (DISEASE ED)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Combined groups (PAIN and DISEASE ED)
Number of subjects: 53
Study: 18283036

Group type: EXPERIMENTAL
Intervention: Pemetrexed 500 mg/m(2) (P500)
Number of subjects: 588

Group type: COMPARATOR
Intervention: Pemetrexed 900 mg/m(2) (P900)
Number of subjects: 588
Study: 15719917

Group type: EXPERIMENTAL
Intervention: Resin‐modified glass ionomer cement (A)
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Flowable resin composite (B)
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Compomer (C)
Number of subjects: 356
Study: 11824857

Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg (increased to 10 mg if needed)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Chlorthalidone 15 mg (increased to 30 mg if needed)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 10071094

Group type: EXPERIMENTAL
Intervention: Strategy aid condition (hint about performance strategies)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No strategy aid condition
Number of subjects: 0
Study: 8613561

Group type: EXPERIMENTAL
Intervention: Antiadhesive (1%)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Antiadhesive with 0.02% chlorhexidine
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine rinse product
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Essential oil/phenolic rinse product
Number of subjects: 15

Group type: COMPARATOR
Intervention: Water
Number of subjects: 15
Study: 2296934

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Milk
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Calcium citrate-malate (CCM)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: CCM plus orange juice
Number of subjects: 19
Study: 443593

Group type: EXPERIMENTAL
Intervention: Pentaerythritol tetranitrate (PETN)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nitroglycerin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Isosorbide dinitrate
Number of subjects: 0
Study: 31827356

Group type: EXPERIMENTAL
Intervention: Inhaled 1600 μg Salbutamol (SAL)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 13
Study: 27662262

Group type: EXPERIMENTAL
Intervention: Domestic assault
Number of subjects: 93

Group type: COMPARATOR
Intervention: Sport
Number of subjects: 93

Group type: COMPARATOR
Intervention: Fall
Number of subjects: 93

Group type: COMPARATOR
Intervention: Motor vehicle accident
Number of subjects: 93
Study: 25345354

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure lowering (systolic target <140 mmHg)
Number of subjects: 404

Group type: COMPARATOR
Intervention: Guideline-recommended blood pressure lowering (systolic target <180 mmHg)
Number of subjects: 404
Study: 23866771

Group type: EXPERIMENTAL
Intervention: Usual DVA agency support plus psychological intervention (SPA sessions weekly or fortnightly, with two follow-up sessions at 1 month and 3 months)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Usual DVA agency support (control)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Usual DVA agency support plus psychological intervention
Number of subjects: 250
Study: 21123311

Group type: EXPERIMENTAL
Intervention: Dutasteride
Number of subjects: 134

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study: 19946937

Group type: EXPERIMENTAL
Intervention: Atypical antipsychotics (aripiprazole and risperidone)
Number of subjects: 24
Study: 17562526

Group type: EXPERIMENTAL
Intervention: 5 mg Diazepam (DZP) in older subjects
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 10 mg Diazepam (DZP) in young subjects
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo in both age groups
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 5 mg Diazepam (DZP) in young subjects
Number of subjects: 15
Study: 11144317

Group type: EXPERIMENTAL
Intervention: Powder breast milk enrichment
Number of subjects: 71

Group type: COMPARATOR
Intervention: Liquid breast milk enrichment
Number of subjects: 71
Study: 8820005

Group type: EXPERIMENTAL
Intervention: Intrauterine insemination
Number of subjects: 62

Group type: COMPARATOR
Intervention: Timed intercourse
Number of subjects: 62
Study: 1279299

Group type: EXPERIMENTAL
Intervention: 2 mg perindopril
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 4 mg perindopril
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 8 mg perindopril
Number of subjects: 24

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study: 2864420

Group type: EXPERIMENTAL
Intervention: Oral phenytoin formulations (5 different formulations, 300 mg each)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Intravenous phenytoin (300 mg)
Number of subjects: 8
Study: 30058950

Group type: EXPERIMENTAL
Intervention: Training intervention (full squats combined with repeated jumps)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 34
Study: 29356001

Group type: EXPERIMENTAL
Intervention: Very early invasive strategy performed within 2 hours
Number of subjects: 740

Group type: COMPARATOR
Intervention: Delayed invasive strategy (coronary angiography between 12 and 72 hours after randomization)
Number of subjects: 740
Study: 27029681

Group type: EXPERIMENTAL
Intervention: Deferiprone alone (75 mg/kg/day in 3 divided doses)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Deferasirox alone (30 mg/kg/day single dose)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Combination therapy (same doses as monotherapy)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 49

Group type: COMPARATOR
Intervention: Deferiprone and Deferasirox (monotherapy and combination)
Number of subjects: 49
Study: 24293660

Group type: EXPERIMENTAL
Intervention: VE-bonded polysulfone membranes
Number of subjects: 260

Group type: COMPARATOR
Intervention: Non-VE-bonded membranes
Number of subjects: 260
Study: 23257371

Group type: EXPERIMENTAL
Intervention: High-dose aspirin (>200 mg daily)
Number of subjects: 2851

Group type: COMPARATOR
Intervention: Low-dose aspirin (≤200 mg daily)
Number of subjects: 2851
Study: 20132540

Group type: EXPERIMENTAL
Intervention: Intensive smoking cessation intervention (brief motivational interview, intensive motivational interview with pharmacotherapy, reinforcing intervention)
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: Intensive smoking cessation intervention
Number of subjects: 546
Study: 17919844

Group type: COMPARATOR
Intervention: PLAFUR (cisplatin + 5-fluorouracil + radiotherapy)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: TOMOX-RT (raltitrexed + oxaliplatin + radiotherapy)
Number of subjects: 164
Study: 15966884

Group type: EXPERIMENTAL
Intervention: Enamel matrix proteins (EMPs, Emdogain Gel)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Tetracycline-coated e-PTFE membrane (MEMP) adjunct to EMP
Number of subjects: 11
Study: 12839637

Group type: EXPERIMENTAL
Intervention: Millimeter wave irradiation and routine medication
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Millimeter wave irradiation
Number of subjects: 80

Group type: COMPARATOR
Intervention: Pretending millimeter wave irradiation and routine medication
Number of subjects: 80

Group type: COMPARATOR
Intervention: Routine medication
Number of subjects: 80
Study: 10341371

Group type: EXPERIMENTAL
Intervention: 160 mg of prednisone (n = 12)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (n = 12)
Number of subjects: 24
Study: 8607399

Group type: EXPERIMENTAL
Intervention: Antioxidant vitamins (A: 50,000 IU/day, C: 1,000 mg/day, E: 400 mg/day, beta-carotene: 25 mg/day)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Antioxidant vitamins
Number of subjects: 125
Study: 2013589

Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression alone
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression and aspirin
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression and low-dose warfarin
Number of subjects: 196

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 196
Study: 30997149

Group type: EXPERIMENTAL
Intervention: Advice to remain active while awaiting physiotherapy
Number of subjects: 538

Group type: COMPARATOR
Intervention: Advice to rest while awaiting physiotherapy
Number of subjects: 538

Group type: COMPARATOR
Intervention: Immediate physiotherapy
Number of subjects: 538
Study: 28993070

Group type: EXPERIMENTAL
Intervention: Soft contact lens (SCL) with central thickness of 0.4mm
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Soft contact lens (SCL) with central thickness of 0.3mm
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Soft contact lens (SCL) with central thickness of 0.1mm, 0.2mm, 0.3mm, and 0.4mm
Number of subjects: 14
Study: 27287084

Group type: EXPERIMENTAL
Intervention: LNG/EE extended regimen (84 days of LNG 150 µg/EE 30 µg with 7 days of EE 10 µg)
Number of subjects: 829

Group type: EXPERIMENTAL
Intervention: LNG/EE 21/7 (21 days of LNG 100 µg/EE 20 µg with 7 days of placebo)
Number of subjects: 829

Group type: COMPARATOR
Intervention: Reference group (not using hormonal contraceptives)
Number of subjects: 829
Study: 24901757

Group type: EXPERIMENTAL
Intervention: Robotic knee brace therapy
Number of subjects: 24

Group type: COMPARATOR
Intervention: Group exercise program
Number of subjects: 24
Study: 22337700

Group type: EXPERIMENTAL
Intervention: POs‐Ca chewing gum
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: POs‐Ca+F chewing gum
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo chewing gum
Number of subjects: 15
Study: 20362755

Group type: EXPERIMENTAL
Intervention: Adalimumab (evaluated in Phase II and Phase III trials)
Number of subjects: 1591
Study: 18818160

Group type: EXPERIMENTAL
Intervention: Purple sweet potato leaves (PSPL) 200 g/d containing 902 mg polyphenols
Number of subjects: 16

Group type: COMPARATOR
Intervention: Low polyphenol diet (LPD)
Number of subjects: 16
Study: 16328673

Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.25% (L-B) for local infiltration and intraperitoneal instillation
Number of subjects: 108

Group type: COMPARATOR
Intervention: Normal saline (NS) for local infiltration and intraperitoneal instillation
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Normal saline (NS) for local infiltration and Levobupivacaine 0.25% (L-B) for intraperitoneal instillation
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.25% (L-B) for intraperitoneal instillation and Normal saline (NS) for local infiltration
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.25% (L-B) for both local infiltration and intraperitoneal instillation
Number of subjects: 108
Study: 14585107

Group type: EXPERIMENTAL
Intervention: Web-based weight loss package
Number of subjects: 180

Group type: COMPARATOR
Intervention: Usual care (traditional dietary treatment)
Number of subjects: 180
Study: 10569338

Group type: EXPERIMENTAL
Intervention: Stent implantation without predilation
Number of subjects: 122

Group type: COMPARATOR
Intervention: Conventional stent implantation (with predilation)
Number of subjects: 122
Study: 8744662

Group type: COMPARATOR
Intervention: Intramuscular injection of 15 mL saline (M)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intramuscular injection of 15 mL 0.5% bupivacaine (MIB)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Epidural injection of 15 mL 0.5% bupivacaine at the L3‐L4 level (MEB)
Number of subjects: 60
Study: 1707013

Group type: EXPERIMENTAL
Intervention: Iloprost (3000 ng injected into the graft over 2 min)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 7048877

Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Pindolol + hydralazine + hydrochlorothiazide + guanethidine
Number of subjects: 300

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300

Group type: COMPARATOR
Intervention: α‐methyldopa/hydrochlorothiazide
Number of subjects: 300
Study: 31578095

Group type: EXPERIMENTAL
Intervention: Bench press exercise at 75% one-repetition maximum
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Bench press exercise at 85% one-repetition maximum
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Bench press exercise at 95% one-repetition maximum
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Bench press exercise (all loads)
Number of subjects: 17
Study: 31671757

Group type: EXPERIMENTAL
Intervention: Iron (5 mg) and Galacto-Oligosaccharides (7.5 g)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Iron (5 mg)
Number of subjects: 80
Study: 27868342

Group type: EXPERIMENTAL
Intervention: 10% price discount on grocery, fruit, vegetables, and diet soft-drinks
Number of subjects: 54
Study: 26017328

Group type: EXPERIMENTAL
Intervention: Diflunisal 500 mg/day
Number of subjects: 40
Study: 24558835

Group type: EXPERIMENTAL
Intervention: Bushen Huoxue Herbs
Number of subjects: 96

Group type: COMPARATOR
Intervention: Western medicine (as basic treatment)
Number of subjects: 96
Study: 21350839

Group type: EXPERIMENTAL
Intervention: rAd2p53 gene therapy + RT (n = 22)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Radiotherapy (n = 23)
Number of subjects: 45
Study: 19340626

Group type: EXPERIMENTAL
Intervention: GnRH agonist
Number of subjects: 136

Group type: COMPARATOR
Intervention: GnRH antagonist
Number of subjects: 136
Study: 17419956

Group type: EXPERIMENTAL
Intervention: Pegaptanib sodium (intra-ocular injection) for 54 weeks, followed by re-randomization to continue or discontinue treatment.
Number of subjects: 1186

Group type: COMPARATOR
Intervention: Control group (sham treatment)
Number of subjects: 1186
Study: 15798250

Group type: EXPERIMENTAL
Intervention: Wrist‐to‐ankle bioimpedance analysis (WBIA) in high BMI group
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Segmental bioimpedance analysis (SBIA) in high BMI group
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Wrist‐to‐ankle bioimpedance analysis (WBIA) in low BMI group
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Segmental bioimpedance analysis (SBIA) in low BMI group
Number of subjects: 25

Group type: COMPARATOR
Intervention: Wrist‐to‐ankle bioimpedance analysis (WBIA) comparison between high and low BMI groups
Number of subjects: 25

Group type: COMPARATOR
Intervention: Segmental bioimpedance analysis (SBIA) comparison between high and low BMI groups
Number of subjects: 25

Group type: COMPARATOR
Intervention: Wrist‐to‐ankle bioimpedance analysis (WBIA)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Segmental bioimpedance analysis (SBIA)
Number of subjects: 25
Study: 12479763

Group type: COMPARATOR
Intervention: Chlorthalidone (12.5 to 25 mg/d)
Number of subjects: 33357

Group type: EXPERIMENTAL
Intervention: Amlodipine (2.5 to 10 mg/d)
Number of subjects: 33357

Group type: EXPERIMENTAL
Intervention: Lisinopril (10 to 40 mg/d)
Number of subjects: 33357
Study: 9489629

Group type: EXPERIMENTAL
Intervention: Autologous peripheral blood stem cell (PBSC) transplantation
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Maintenance treatment with recombinant alpha interferon (IFN-alpha)
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Overall survival (OS)
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Progression-free survival (PFS)
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Transplant-related mortality
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Pretransplant response status
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Female sex and pretransplant responsive disease
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Number of chemotherapy courses prior to autologous PBSC transplantation
Number of subjects: 259
Study: 8106695

Group type: EXPERIMENTAL
Intervention: Intensive lipid-lowering therapy
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 120
Study: 2506608

Group type: EXPERIMENTAL
Intervention: Alprazolam (AL; 0.25 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Lorazepam (LO; 1 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 6